CNSP earnings date and last-quarter result: next report 2026-08-17, last quarter miss, P/E -0.20. Updated 2026-07-23.
CNS Pharmaceuticals (CNSP) Research Hub
CNS Pharmaceuticals (CNSP) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.63 USD (-6.84%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.20, market cap 0.00B. This hub links to the full technical, earnings and options research available for CNSP.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.63 USD (-6.84%) |
| 52-week range | 3.67 USD – 6.19 USD |
| Trend regime | Range |
| 14-day RSI | 37.2 (Bearish) |
| Trailing P/E | -0.20 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-17 |
Available research for CNSP
Covered Call on CNSP: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CNSP: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CNSP: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
CNSP technical analysis: range, last 4.63 USD, RSI 37.2, 52w range 3.67 USD–6.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CNSP in?
CNS Pharmaceuticals (CNSP) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CNSP in an uptrend or downtrend?
As of 2026-10-26, CNSP is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CNSP's trailing P/E ratio?
CNSP's trailing P/E is -0.20, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does CNSP next report earnings?
CNSP is next scheduled to report earnings on 2026-08-17.